Daniel Gallagher - Viatris Chief Legal Officer

Executive

Mr. Daniel M. Gallagher is Chief Legal Officer of the Company. He previously served as president of Patomak Global Partners, a consulting firm providing strategic advice, compliance consulting, and litigation and regulatory enforcement services, from January 2016 to March 2017. As president, Mr. Gallagher was responsible for originating and managing client matters, and assisting the Chief Executive Officer in overseeing operations of the firm. From November 2011 to October 2015, Mr. Gallagher served as a commissioner of the SEC. During his tenure at the SEC, Mr. Gallagher focused on initiatives aimed at strengthening the U.S. capital markets and encouraging capital formation, among others. Before being appointed commissioner, Mr. Gallagher served on the staff of the SEC in several capacities, including as counsel to both SEC Commissioner Paul Atkins and Chairman Christopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Mr. Gallagher served as deputy director and coacting director of the Division of Trading and Markets from 2008 to 2010. In addition to his tenure in public service, Mr. Gallagher spent a number of years in the private sector. Following law school, he joined the Washington, D.C. law firm Wilmer Cutler Pickering. He later returned to Wilmer as a partner following his staff service at the SEC. Mr. Gallagher also served as senior vice president and general counsel of Fiserv Securities, Inc., where he was responsible for managing all of the firms legal and regulatory matters. Mr. Gallagher serves as nonexecutive director of both the Irish Stock Exchange and Symbiont.io, and is on the advisory board of the Drexel LeBow Center for Corporationrationrate Governance. since 2017.
Age 44
Tenure 7 years
Phone44 1707 853 000
Webhttp://www.mylan.com

Viatris Management Efficiency

The company has Return on Asset of 3.63 % which means that on every $100 spent on assets, it made $3.63 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 2.22 %, implying that it generated $2.22 on every 100 dollars invested. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 12.51 B in debt with debt to equity (D/E) ratio of 1.0, which is OK given its current industry classification. Viatris has a current ratio of 0.99, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Viatris until it has trouble settling it off, either with new capital or with free cash flow. So, Viatris' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viatris sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viatris to invest in growth at high rates of return. When we think about Viatris' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Lauren McNamaraSunOpta
N/A
Christopher WhitehairSunOpta
57
Justin KoblerSunOpta
N/A
Chad HagenSunOpta
N/A
Roni CappadonnaSea
N/A
David ChenSea
N/A
Bryan ClarkSunOpta
N/A
Rob DuchscherSunOpta
62
Robert DuchscherSunOpta
56
Reginald HedgebethSea
47
Alan HellawellSea
N/A
Guy BuckleySea
54
Franck BaduelGenuine Parts Co
N/A
Julie DillSea
55
Sidney JonesGenuine Parts Co
N/A
Yanjun WangSea
38
Joseph SuarezConstellation Brands Class
N/A
Dorothy AblesSea
57
Kristann CareyConstellation Brands Class
54
Michael BeckaConstellation Brands Class
N/A
Scott LeprohonGenuine Parts Co
N/A
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter pharmaceutical products in North America, Europe, and internationally. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Mylan NV operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 35000 people. Viatris (MYL) is traded on NASDAQ Exchange in USA and employs 35,000 people.

Management Performance

Viatris Leadership Team

Elected by the shareholders, the Viatris' board of directors comprises two types of representatives: Viatris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viatris. The board's role is to monitor Viatris' management team and ensure that shareholders' interests are well served. Viatris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viatris' outside directors are responsible for providing unbiased perspectives on the board's policies.
Anthony Mauro, President of Mylan North America
Joseph Maroon, Independent Director
Kris King, VP of Global Investor Relations
Heather Bresch, CEO, Executive Director and Member of Science and Technology Committee
Harry Korman, Non-Executive Independent Director
Melina Higgins, Independent Director
Mark Parrish, Independent Director
Kenneth Parks, CFO
Rodney Piatt, Vice Chairman of the Board, Lead Independent Director
Rajiv Malik, President, Executive Director and Member of Science and Technology Committee
John Sheehan, Executive Vice President CFO, Principal Financial officer
Dennis Zeleny, Chief Human Resource Officer
JoEllen Dillon, Independent Director
Neil Dimick, Independent Director
Sjoerd Vollebregt, Independent Director
Douglas Leech, Independent Director
Robert Cindrich, Independent Director
Pauline Mohr, Non-Executive Independent Director
Wendy Cameron, Independent Director
Rakesh Bamzai, President - India Commercial and Emerging Markets
Robert Coury, Executive Chairman and Chairman of Executive Committee
Daniel Gallagher, Chief Legal Officer
Richard Mark, Non-Executive Independent Director
Randall Vanderveen, Independent Director

Viatris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viatris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Consideration for investing in Viatris Stock

If you are still planning to invest in Viatris check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viatris' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance